At the AGM four injectable products were highlighted as having...

At the AGM four injectable products were highlighted as having passed six month stability tests and were now subject to business development activity.Shareholders are not privy as to why these injectables were chosen for TPM enhancement or much detail in relation to the particular injectables intended use.
A brief overview of each of the selected four injectables is given below to clarify some issues:
1.Vitamin K-for new babies injection to prevent blood clotting-also heavily used in vetinary practice.Vitamin K administered incorrectly has caused deaths in the past.
2.Clopidogrel-is used to prevent heart attack and stroke in people affected with heart disease.Major pharma products are under attack from generics competition.
3.Azithromycin-antibiotic works by killing bacteria or preventing growth-does not work on colds or flu.Generic competition is apparent for majors.
4.Melphalan-is used to treat bone marrow cancer and is a chemotherapy drug.The trade name for this product is Evomela.

Products at 2 and 3 appear to have an approach not unlike that which was taken with the development of the daptomycin injectable.
Vitamin K may have been an each way bet between human and animal health.
Melphalan is obviously widely used as a chemotherapy drug.
Kens​